Effects of chronic treatment with a GnRH agonist on oestrous behaviour and on the secretion of LH and progesterone in the ewe.

Effects of chronic treatment with a GnRH agonist on oestrous behaviour and on the secretion of LH and progesterone in the ewe. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Effects of chronic treatment with a GnRH agonist on oestrous behaviour and on the secretion of LH and progesterone in the ewe. Abstract Text:

H Dobson,

A study was carried out to investigate a novel approach to oestrus synchronization in the ewe by treatment with a gonadotrophin releasing hormone (GnRH) agonist. Groups of ewes were initially treated on Day 2, 10 or 14 of the oestrous cycle with 10 mug GnRH analogue (D-Ser(Bu(t)) 6 des Gly GnRH ethylamide) per ewe per day for 14 days. Behavioural oestrus was inhibited during GnRH agonist treatment and recurred from 8 to 38 days after the treatment in an unsynchronized manner. Luteal activity during treatment was not impaired but reduced progesterone concentrations occurred in cycles after the treatment. The rhythm of ovarian function, generally characterized by prolonged follicular development, was impaired. During the treatment and subsequent recovery period, integrity of pituitary function was examined by measuring luteinizing hormone (LH) after GnRH agonist was injected, and after stimulation test doses of 150 ng natural GnRH were administered. During treatment there was, with time, a decline in pituitary response to the agonist which suggested that pituitary release of LH was exhausted. After the 14-day treatment the stimulation test with GnRH revealed a gradual return to normal responsiveness although this was not complete three weeks after the treatment when compared to control ewes. This lowered pituitary activity could cause the impaired ovarian function.

Effects of chronic treatment with a GnRH agonist on oestrous behaviour and on the secretion of LH and progesterone in the ewe. Publishing Authors By Initials

H Dobson,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Effects of chronic treatment with a GnRH agonist on oestrous behaviour and on the secretion of LH and progesterone in the ewe. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Theriogenology

VOLUME: 24

Page Numbers: 1-11

Journal Abbreviation: Theriogenology

ISSN: 0093-691X

DAY: 26

MONTH: Jul

YEAR: 1985

Effects of chronic treatment with a GnRH agonist on oestrous behaviour and on the secretion of LH and progesterone in the ewe. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 421510

Effects of chronic treatment with a GnRH agonist on oestrous behaviour and on the secretion of LH and progesterone in the ewe. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Effects of chronic treatment with a GnRH agonist on oestrous behaviour and on the secretion of LH and progesterone in the ewe. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Effects of chronic treatment with a GnRH agonist on oestrous behaviour and on the secretion of LH and progesterone in the ewe.

AFFILIATION: Department of Veterinary Clinical Science, University of Liverpool, Leahurst, Neston, South Wirral, L64 7TE, England.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Theriogenology

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Effects of chronic treatment with a GnRH agonist on oestrous behaviour and on the secretion of LH and progesterone in the ewe Related Publications

• A lifestyle view of life-history evolution.
• Achievement of Energy Focus for Distance-of-Flight Mass Spectrometry with Constant Momentum Acceleration and an Ion Mirror.
• Adenosine A1 and A2A receptor effects on G-protein cycling in beta-adrenergic stimulated ventricular membranes.
• Agency urges researchers to make more use of yellow card data.
• An experimental investigation of the cognitive vulnerability to depression.
• An overview of faecal incontinence in children.
• Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity.
• CONVERGENCE.
• Dexamethasone and ondansetron incompatibility in polypropylene syringes.
• Early pituitary follicle stimulating hormone response to gonadotrophin releasing hormone in ewes.
• Economic cost of difficult calvings in the United Kingdom dairy herd.
• Effects of chronic treatment with a GnRH agonist on oestrous behaviour and on the secretion of LH and progesterone in the ewe.
• England and Wales are among European countries at highest risk of measles epidemic.
• HEPATIC CUTANEOUS PORPHYRIA. RESPONSE OF A PATIENT TO TREATMENT WITH ADENOSINE-5-MONOPHOSPHATE.
• Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation.
• Human papillomavirus vaccines: who should get them and why?
• Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations.
• Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent.
• Nocturnal enuresis in children.
• Perceptions of Saskatchewan community pharmacists regarding a prior-authorization program.
• Preconditioning and postconditioning: innate cardioprotection from ischemia-reperfusion injury.
• Projected impacts of climate and land-use change on the global diversity of birds.
• Rose revisited: a "middle road" prevention strategy to reduce noncommunicable chronic disease risk.
• Study shows effect on life expectancy of greater spending on treatment.
• Teller Acuity Card norms with and without use of a testing stage.
• Training the trainers.
• Unnecessary C-sections.
• Variation in number of women being recalled after breast cancer screening needs to be looked into.
• Weighted multimorbidity indexes predicted mortality, health service use, and health-related quality of life in older women.
• gamma-amino butyric acid control of arginine vasopressin release from the ewe hypothalamus in vitro: sensitivity to oestradiol.